Endotoxin preconditioning prevents cellular inflammatory response during ischemic neuroprotection in mice
HL Rosenzweig, NS Lessov, DC Henshall, M Minami… - Stroke, 2004 - Am Heart Assoc
HL Rosenzweig, NS Lessov, DC Henshall, M Minami, RP Simon, MP Stenzel-Poore
Stroke, 2004•Am Heart AssocBackground and Purpose—Tolerance to ischemic brain injury is induced by several
preconditioning stimuli, including lipopolysaccharide (LPS). A small dose of LPS given
systemically confers ischemic protection in the brain, a process that appears to involve
activation of an inflammatory response before ischemia. We postulated that LPS
preconditioning modulates the cellular inflammatory response after cerebral ischemia,
resulting in neuroprotection. Methods—Mice were treated with LPS (0.2 mg/kg) 48 hours …
preconditioning stimuli, including lipopolysaccharide (LPS). A small dose of LPS given
systemically confers ischemic protection in the brain, a process that appears to involve
activation of an inflammatory response before ischemia. We postulated that LPS
preconditioning modulates the cellular inflammatory response after cerebral ischemia,
resulting in neuroprotection. Methods—Mice were treated with LPS (0.2 mg/kg) 48 hours …
Background and Purpose— Tolerance to ischemic brain injury is induced by several preconditioning stimuli, including lipopolysaccharide (LPS). A small dose of LPS given systemically confers ischemic protection in the brain, a process that appears to involve activation of an inflammatory response before ischemia. We postulated that LPS preconditioning modulates the cellular inflammatory response after cerebral ischemia, resulting in neuroprotection.
Methods— Mice were treated with LPS (0.2 mg/kg) 48 hours before ischemia induced by transient middle cerebral artery occlusion (MCAO). The infarct was measured by 2,3,5-triphenyltetrazolium chloride staining. Microglia/macrophage responses after MCAO were assessed by immunofluorescence and flow cytometry. The effect of MCAO on white blood cells in the brain and peripheral circulation was measured by flow cytometry 48 hours after MCAO.
Results— LPS preconditioning induced significant neuroprotection against MCAO. Administration of low-dose LPS before MCAO prevented the cellular inflammatory response in the brain and blood. Specifically, LPS preconditioning suppressed neutrophil infiltration into the brain and microglia/macrophage activation in the ischemic hemisphere, which was paralleled by suppressed monocyte activation in the peripheral blood.
Conclusions— LPS preconditioning induces neuroprotection against ischemic brain injury in a mouse model of stroke. LPS preconditioning suppresses the cellular inflammatory response to ischemia in the brain and circulation. Diminished activation of cellular inflammatory responses that ordinarily exacerbate ischemic injury may contribute to neuroprotection induced by LPS preconditioning.
Am Heart Assoc